Leishmaniasis is a vector-borne disease caused by the protozoan parasite found in tropical and sub-tropical areas, affecting 12 million people around the world. Only few treatments are available against this disease and all of them present issues of toxicity and/or resistance. In this context, the development of new antileishmanial drugs specifically directed against a therapeutic target appears to be a promising strategy.
View Article and Find Full Text PDF